Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.

Abstract

Arsenic trioxide (ATO), one of the oldest remedies used in traditional medicine, was recently rediscovered as an anticancer drug and approved for treatment of relapsed acute promyelocytic leukemia. However, its activity against nonhematologic cancers is rather limited so far. Here, we show that inhibition of ATO-mediated EGF receptor (EGFR) activation can be used to potently sensitize diverse solid cancer types against ATO. Thus, combination of ATO and the EGFR inhibitor erlotinib exerted synergistic activity against multiple cancer cell lines. Subsequent analyses revealed that this effect was based on the blockade of ATO-induced EGFR phosphorylation leading to more pronounced G2-M arrest as well as enhanced and more rapid induction of apoptosis. Comparable ATO-sensitizing effects were also found with PI3K/AKT and mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, suggesting an essential role of the EGFR-mediated downstream signaling pathway in cancer cell protection against ATO. H2AX staining and comet assay revealed that erlotinib significantly increases ATO-induced DNA double-strand breaks (DSB) well in accordance with a role of the EGFR signaling axis in DNA damage repair. Indeed, EGFR inhibition led to downregulation of several DNA DSB repair proteins such as Rad51 and Rad50 as well as reduced phosphorylation of BRCA1. Finally, the combination treatment of ATO and erlotinib was also distinctly superior to both monotreatments against the notoriously therapy-resistant human A549 lung cancer and the orthotopic p31 mesothelioma xenograft model in vivo. In conclusion, this study suggests that combination of ATO and EGFR inhibitors is a promising therapeutic strategy against various solid tumors harboring wild-type EGFR.

• Authors: Kushtrim Kryeziu, Ute Jungwirth, Mir Alireza Hoda, Franziska Ferk, Siegfried Knasmüller, Claudia Karnthaler-Benbakka, Christian R Kowol, Walter Berger, Petra Heffeter
• Journal: Molecular cancer therapeutics (Mol Cancer Ther) Vol. 12 Issue 6 Pg. 1073-84 (Jun 2013) ISSN: 1538-8514 [Electronic] United States
• PMID: 23548265 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: ©2013 AACR

Chemical References

• Arsenicals
• BRCA1 Protein
• BRCA1 protein, human
• DNA-Binding Proteins
• Oxides
• Quinazolines
• Erlotinib Hydrochloride
• EGFR protein, human
• ErbB Receptors
• Rad51 Recombinase
• Acid Anhydride Hydrolases
• RAD50 protein, human
• DNA Repair Enzymes
• Arsenic Trioxide

Topics

• Acid Anhydride Hydrolases
• Animals
• Arsenic Trioxide
• Arsenicals (pharmacology)
• BRCA1 Protein (biosynthesis)
• DNA Breaks, Double-Stranded (drug effects)
• DNA Repair (drug effects, genetics)
• DNA Repair Enzymes (biosynthesis)
• DNA-Binding Proteins (biosynthesis)
• Drug Synergism
• ErbB Receptors (antagonists & inhibitors, genetics, metabolism)
• Erlotinib Hydrochloride
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Mice
• Neoplasms (drug therapy, genetics, pathology)
• Oxides (pharmacology)
• Phosphorylation (drug effects)
• Quinazolines (pharmacology)
• Rad51 Recombinase (biosynthesis)
• Signal Transduction (drug effects, genetics)
• Xenograft Model Antitumor Assays